You searched for morphosys

morphosys genmab janssen cancer immunotherapy

News and Trends 28 Jan 2019

Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents

…MorphoSys began the dispute over Darzalex (daratumumab), Genmab and Janssen’s approved antibody therapy for the blood cancer multiple myeloma. MorphoSys alleged that Darzalex infringed on three of its patents regarding…

January 28, 2019 - 3 minutesmins - By Dani Bancroft

Interview 12 Feb 2018

MorphoSys’ CEO Tells Us What’s Next for Europe’s Antibody Expert

…else has been key to MorphoSys’ success? I followed up Philip’s previous interviews with Moroney and MorphoSys’ first approval last fall and found out what we can look forward to…

February 12, 2018 - 8 minutesmins - By Alex Dale

News and Trends 18 Jan 2016

Inside Biotech’s Most Secretive Elite Conference: MorphoSys Talks on Investor Speed Dating in California

…the day). And then, of course, there is the constant battle against jet lag… Claudia Gutjahr-Löser is Head of Corporate Relations and Investor Relations at MorphoSys in Munich (© MorphoSys)…

January 18, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 27 Apr 2016

‘Disappointing results’ for Novartis & MorphoSys phase III in Muscle Disease

…MorphoSys. The two companies are developing bimagrumab for muscle diseases, as part of their ongoing collaboration, which has already resulted in 11 programmes. Bimagrumab was initially created by MorphoSys, a…

April 27, 2016 - 2 minutesmins - By Denise Neves Gameiro

Interview 12 Apr 2017

Video Interview: How Morphosys Grew Into a Billion-Euro Biotech

…biotech in Germany, Morphosys. Their topics ranged from Morphosys’ current pipeline and previous failures to the immuno-oncology hype and company culture. Morphosys started out with its proprietary antibody technology platform…

April 12, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 19 May 2017

MorphoSys’ First Lanthipeptide Completes Phase I Successfully

UPDATE (19/05/2017): MorphoSys has announced the completion of the Phase I study with MOR107, which has proved safe and showed dose-dependent pharmacokinetics. The drug, an agonist of the angiotensin II…

May 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Morphosys Janssen Guselkumab approval psoriasis

News and Trends 18 Sep 2017

Update: After 25 years, MorphoSys Gets its First Antibody Approved

…psoriasis, bringing the first antibody developed by MorphoSys to the market. After celebrating its 25th anniversary last week, MorphoSys is welcoming the approval of the first antibody developed using its…

September 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Mar 2018

Can MorphoSys’ Alzheimer’s Treatment Work Where Big Pharma has Failed?

Roche has positive clinical data in support of starting a Phase III trial in Alzheimer’s with an antibody initially developed by MorphoSys. However, the field is full of similar approaches…

March 15, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 29 Oct 2019

MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II

Development of MorphoSys, Galapagos, and Novartis’ first-in-class antibody drug has been discontinued during a phase II trial after an interim analysis suggested it wouldn’t meet its main endpoint of reducing…

October 29, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 20 Feb 2018

Morphosys and Galapagos Announce Positive Phase I Results for Atopic Dermatitis Treatment

Phase I results show promise for a new treatment for atopic dermatitis that may become a strong competitor to the market leader, Humira. Morphosys and Galapagos are developing an antibody…

February 20, 2018 - 3 minutesmins - By Alexander Burik

roche morphosys antibody alzheimers gantenerumab 1

News and Trends 14 Mar 2017

Can Roche & MorphoSys beat the odds in new Alzheimer’s Phase III Trials?

After recent late-stage disappointments from Eli Lilly and Merck, Roche and Morphosys are stepping up with two new Phase III trials in Alzheimer’s. Roche just announced plans to start two…

March 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Nov 2015

Exclusive from BIO-Europe 2015: Interview of Simon Moroney, CEO of leading German Biotech MorphoSys

…of MorphoSys (part of our top 9 EU-based billion euros Biotechs). The Munich-based company was founded in 1992 and now counts +-350 employees for a market cap of roughly 1.5…

November 2, 2015 - 1 minutemin - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: morphosys

Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents

MorphoSys’ CEO Tells Us What’s Next for Europe’s Antibody Expert

Inside Biotech’s Most Secretive Elite Conference: MorphoSys Talks on Investor Speed Dating in California

‘Disappointing results’ for Novartis & MorphoSys phase III in Muscle Disease

Video Interview: How Morphosys Grew Into a Billion-Euro Biotech

MorphoSys’ First Lanthipeptide Completes Phase I Successfully

Update: After 25 years, MorphoSys Gets its First Antibody Approved

Can MorphoSys’ Alzheimer’s Treatment Work Where Big Pharma has Failed?

MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II

Morphosys and Galapagos Announce Positive Phase I Results for Atopic Dermatitis Treatment

Can Roche & MorphoSys beat the odds in new Alzheimer’s Phase III Trials?

Exclusive from BIO-Europe 2015: Interview of Simon Moroney, CEO of leading German Biotech MorphoSys

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!